There are currently 128 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT06582849
Recruiting
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing \>10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants to historic controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Register for Updates
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04588025
Recruiting
The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
10/07/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT03551951
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Harry S Truman Veterans Memorial Hospital, Columbia, Missouri
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri
Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Karmanos Cancer Center, Detroit, Michigan +7 locations
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
NCT06323291
Recruiting
This Pilot Study will evaluate a 12-week pilot program that offers digital health coaching for individuals with pancreatic cancer and their caregivers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
UCSF PANC Cyst Registry
NCT04291651
Recruiting
Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Diseases, Pancreatic Ductal Adenocarcinoma, Mucinous Cyst, Pancreatic Intraductal Papillary Mucinous Neoplasm, Intraductal Papillary Mucinous Neoplasm
Register for Updates
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Sarah Cannon Research Institute, Denver, Colorado +3 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
Register for Updates
Artificial Inteligence in Endoscopic Ultrasound
NCT06564571
Recruiting
The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/19/2024
Locations: Orlando Health, Orlando, Florida
Conditions: Pancreatic Cancer, Pancreas Disease, Pancreatic Cyst
Register for Updates
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
NCT05632328
Recruiting
The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy. The names of the study drugs involved in this study are: * AGEN1423 * Botensilimab Participants will receive study treatment for about 2 years and will be followed for 1 year... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Register for Updates
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT05013216
Recruiting
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/06/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: High Risk Cancer, Pancreatic Cancer
Register for Updates
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
NCT06001658
Recruiting
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: SKCCC Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates